These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 34481182)

  • 1. Erythropoiesis stimulating agent recommendation model using recurrent neural networks for patient with kidney failure with replacement therapy.
    Yun HR; Lee G; Jeon MJ; Kim HW; Joo YS; Kim H; Chang TI; Park JT; Han SH; Kang SW; Kim W; Yoo TH
    Comput Biol Med; 2021 Oct; 137():104718. PubMed ID: 34481182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience
.
    Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
    Clin Nephrol; 2018 Oct; 90(4):276-285. PubMed ID: 30049300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
    J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study.
    Martínez-Castelao A; Cases A; Carballada AT; Iranzo JT; Bronsoms J; Vallès-Prats M; Monserrat DT; Jimenez EM;
    Nefrologia; 2015; 35(2):179-88. PubMed ID: 26300512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
    Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
    Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.
    Ingrasciotta Y; Giorgianni F; Marcianò I; Bolcato J; Pirolo R; Chinellato A; Ientile V; Santoro D; Genazzani AA; Alibrandi A; Fontana A; Caputi AP; Trifirò G
    PLoS One; 2016; 11(5):e0155805. PubMed ID: 27187174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients.
    Minutolo R; Conte G; Cianciaruso B; Bellizzi V; Camocardi A; De Paola L; De Nicola L
    Nephrol Dial Transplant; 2012 Jul; 27(7):2880-6. PubMed ID: 22319218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
    Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
    Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM Study.
    Akizawa T; Tsubakihara Y; Hirakata H; Watanabe Y; Hase H; Nishi S; Babazono T; Kumagai M; Katakura S; Uemura Y; Ohashi Y;
    Clin Exp Nephrol; 2016 Dec; 20(6):885-895. PubMed ID: 26779906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients.
    Kwon O; Jang HM; Jung HY; Kim YS; Kang SW; Yang CW; Kim NH; Choi JY; Cho JH; Kim CD; Kim YL; Park SH;
    PLoS One; 2015; 10(10):e0140241. PubMed ID: 26452232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients.
    Sánchez-Escuredo A; Batista F; Cases A; Torregrosa JV
    Transplant Proc; 2015; 47(1):73-5. PubMed ID: 25645774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study.
    Panichi V; Scatena A; Rosati A; Giusti R; Ferro G; Malagnino E; Capitanini A; Piluso A; Conti P; Bernabini G; Migliori M; Caiani D; Tetta C; Casani A; Betti G; Pizzarelli F
    Nephrol Dial Transplant; 2015 Apr; 30(4):682-9. PubMed ID: 25385719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009.
    Regidor D; McClellan WM; Kewalramani R; Sharma A; Bradbury BD
    Nephrol Dial Transplant; 2011 May; 26(5):1583-91. PubMed ID: 20861195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anemia trials in CKD and clinical practice: refining the approach to erythropoiesis-stimulating agents.
    de Francisco ALM; Piñera C
    Contrib Nephrol; 2011; 171():248-254. PubMed ID: 21625120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
    Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study.
    Aapro M; Ludwig H; Bokemeyer C; MacDonald K; Soubeyran P; Turner M; Albrecht T; Abraham I
    Ann Oncol; 2009 Oct; 20(10):1714-21. PubMed ID: 19570966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.
    Ingrasciotta Y; Lacava V; Marcianò I; Giorgianni F; Tripepi G; D' Arrigo G; Chinellato A; Ugo Tari D; Santoro D; Trifirò G
    BMC Nephrol; 2019 Sep; 20(1):359. PubMed ID: 31521117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model predictive control of erythropoietin administration in the anemia of ESRD.
    Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
    Am J Kidney Dis; 2008 Jan; 51(1):71-9. PubMed ID: 18155535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study).
    Hayashi T; Uemura Y; Kumagai M; Kimpara M; Kanno H; Ohashi Y;
    Clin Exp Nephrol; 2019 Mar; 23(3):349-361. PubMed ID: 30291472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.